Author

Andrew D. Kelly

Foundation Medicine (United States)ORCID 0000-0002-5338-7689Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

Benjamin Haibe‐KainsiD· 3 shared Christopher E. LietziD· 3 shared Dimitrios SpentzosiD· 3 shared Edwin ChoyiD· 3 shared Gregory Michael CoteiD· 3 shared David H. EbbiD· 2 shared David Haosen XiangiD· 2 shared Erik T. NewmaniD· 2 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenetic & Genomic Medicine

Benjamin Haibe‐KainsORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics.

Christopher E. Lietz, Erik T. Newman, Andrew D. Kelly, David Haosen Xiang, Ziying Zhang, Nikhil Ramavenkat, Joshua J. Bowers, Santiago A. Lozano‐Calderón, David H. Ebb, Kevin A. Raskin, Gregory Michael Cote, Edwin Choy, G. Petur Nielsen, Ioannis S. Vlachos, Benjamin Haibe‐Kains, Dimitrios Spentzos

The paper identifies a dynamic microRNA profile associated with chemotherapy resistance in osteosarcoma and predicts novel therapeutic targets that could reverse resistance.

medRxiv · Jun 19, 2024 · PreprintGenetic & Genomic Medicine

Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in osteosarcoma.

Christopher E. Lietz, Erik T. Newman, Andrew D. Kelly, David Haosen Xiang, Ziying Zhang, Caroline A. Luscko, Santiago A. Lozano‐Calderón, David H. Ebb, Kevin A. Raskin, Gregory Michael Cote, Edwin Choy, G. Petur Nielsen, Benjamin Haibe‐Kains, Martin J. Aryee, Dimitrios Spentzos

This study identifies DNA methylation subtypes in osteosarcoma that predict clinical outcomes and response to chemotherapy.

Communications Biology · Mar 8, 2022Peer-reviewedGenetic & Genomic Medicine

Machine learning-based prediction of response to PARP inhibition across cancer types.

Katherine E. Hill, Ahmed Rattani, Christopher E. Lietz, Cassandra C. Garbutt, Edwin Choy, Gregory Michael Cote, Aedín C. Culhane, Andrew D. Kelly, Benjamin Haibe‐Kains, Dimitrios Spentzos

The paper develops a multi-gene signature predicting PARP inhibitor response across cancer types using machine learning and validates it in vitro and in clinical datasets.

medRxiv · Sep 27, 2019 · PreprintGenetic & Genomic Medicine